Literature DB >> 14659087

Bringing order to the glutamate chaos in schizophrenia.

Bita Moghaddam1.   

Abstract

Recent genetic linkage studies complement the existing evidence that implicates abnormalities in NMDA receptor-mediated neurotransmission in the pathophysiology of schizophrenia. At the same time, advances in our understanding of the complex mechanisms that modulate the function of NMDA receptors suggest several novel sites for pharmacological manipulation of these receptors. This presents exciting opportunities for rational rather than serendipitous discovery of therapeutics for schizophrenia.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14659087     DOI： 10.1016/s0896-6273(03)00757-8

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  123 in total

1.  Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.

Authors:  Eunice Y Yuen; Jing Wei; Wenhua Liu; Ping Zhong; Xiangning Li; Zhen Yan
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

Review 2.  Gene-environment interplay in schizopsychotic disorders.

Authors:  Tomas Palomo; Trevor Archer; Richard M Kostrzewa; Rrichard J Beninger
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 3.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 4.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

5.  Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.

Authors:  Mark R Stefani; Bita Moghaddam
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

6.  Genetic variation in G72 correlates with brain activation in the right middle temporal gyrus in a verbal fluency task in healthy individuals.

Authors:  Axel Krug; Valentin Markov; Sören Krach; Andreas Jansen; Klaus Zerres; Thomas Eggermann; Tony Stöcker; N Jon Shah; Markus M Nöthen; Alexander Georgi; Jana Strohmaier; Marcella Rietschel; Tilo Kircher
Journal:  Hum Brain Mapp       Date:  2011-01       Impact factor: 5.038

Review 7.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder.

Authors:  A Guidotti; J Auta; Y Chen; J M Davis; E Dong; D P Gavin; D R Grayson; F Matrisciano; G Pinna; R Satta; R P Sharma; L Tremolizzo; P Tueting
Journal:  Neuropharmacology       Date:  2010-11-11       Impact factor: 5.250

Review 8.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 9.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 10.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.